Zymeworks Shareholders Back Directors, Executive Pay and Auditor

Zymeworks ( (ZYME) ) has issued an announcement.

On December 30, 2025, Zymeworks Inc. held its 2025 annual meeting of stockholders via virtual webcast, with approximately 83.86% of total voting power represented, constituting a quorum. Securityholders elected directors Carlos Campoy, Alessandra Cesano and Robert E. Landry to the board, approved on an advisory basis the compensation of the company’s named executive officers, and ratified the appointment of KPMG LLP as auditor for the fiscal year ending December 31, 2025, signaling broad shareholder support for the company’s current leadership, executive pay practices, and external audit arrangements.

The most recent analyst rating on (ZYME) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.

Spark’s Take on ZYME Stock

According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.

Zymeworks’ overall stock score is driven by strong technical momentum and positive corporate events, which are somewhat offset by poor valuation metrics and financial performance challenges. The company’s strategic initiatives and clinical progress provide a positive outlook, but profitability and cash flow issues remain significant risks.

To see Spark’s full report on ZYME stock, click here.

More about Zymeworks

Zymeworks Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies, with its capital structure including both common stock and exchangeable shares issued through its indirect subsidiary Zymeworks ExchangeCo Ltd. in British Columbia, reflecting a cross-border corporate and shareholder base.

Average Trading Volume: 1,139,223

Technical Sentiment Signal: Buy

Current Market Cap: $2.02B

Find detailed analytics on ZYME stock on TipRanks’ Stock Analysis page.